Drugs.com Clinical Trial ResultsOriginal article
Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1
Phase 3positiveEncaleretPositive
AI Analysis
Summary
BridgeBio Pharma reported that encaleret increased bone turnover and improved participant-reported symptoms in the Phase 3 CALIBRATE trial in autosomal dominant hypocalcemia type 1 (ADH1).
Clinical Trial Data
Phase
Phase 3
Outcome Details
Encaleret increased bone turnover and improved participant-reported symptoms in the Phase 3 CALIBRATE trial in ADH1.
Importance:6/10
Sentiment:
0.60
Phase 3ADH1encaleretCALIBRATErare diseaseendocrinology
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on October 11, 2026 9:10 PM